hydroxyflutamide has been researched along with mdv 3100 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cen, S; He, Y; Hu, L; Li, Q; Li, X; Liu, Y; Wu, M; Zhou, J | 1 |
| Endo, S; Fujii, S; Fujimoto, N; Gouda, H; Hu, D; Iguchi, K; Ikari, A; Irie, K; Kawai, M; Matsukawa, T; Matsunaga, T; Nakayama, T; Oguri, H; Okada, T; Segawa, J; Toyooka, N; Xia, S | 1 |
| Wang, S; Xiang, W | 1 |
| Culig, Z | 1 |
| Awrey, S; Azad, AA; Cherkasov, A; Chi, KN; Collins, CC; Gleave, ME; Lallous, N; LeBihan, S; Leblanc, E; Murillo, J; Rennie, PS; Singh, K; Tse, R; Volik, SV; Wyatt, AW | 1 |
| El-Shishtawy, KA; Ide, H; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Reis, LO; Zheng, Y | 1 |
2 review(s) available for hydroxyflutamide and mdv 3100
| Article | Year |
|---|---|
Therapeutic Strategies to Target the Androgen Receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
Targeting the androgen receptor in prostate cancer.
Topics: Androgen Antagonists; Anilides; Antibodies, Neutralizing; Anticarcinogenic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Curcumin; Flutamide; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tosyl Compounds | 2014 |
4 other study(ies) available for hydroxyflutamide and mdv 3100
| Article | Year |
|---|---|
Identification of Triptophenolide from
Topics: | 2016 |
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice, Inbred BALB C; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays | 2020 |
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Topics: Androgen Receptor Antagonists; Anilides; Benzamides; DNA; Drug Resistance, Neoplasm; Flutamide; High-Throughput Nucleotide Sequencing; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds | 2016 |
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dihydrotestosterone; Down-Regulation; Flutamide; Humans; Interleukin-6; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Receptors, Androgen; RNA; Tosyl Compounds; Transcription, Genetic; Urinary Bladder Neoplasms | 2016 |